The abstract is read at the publisher; the summary is JClub's.
Combination therapy in HFrEF predicts a short-term systolic blood pressure reduction of -9.2 mmHg (95% prediction interval -10.6 to -7.8) with ARNI + SGLT2i + sMRA.
- Why it matters: Clinicians often hesitate to start comprehensive heart failure regimens because of worries about hypotension, kidney impairment, and hyperkalemia.
- What they did: A pooled individual participant-level prediction model used 38,753 participants from nine randomized trials to estimate 2–12 week effects of ARNI, sMRA, nsMRA, and SGLT2i on SBP, eGFR, and serum potassium.
- The result: The model also predicts short-term eGFR change of -6.8 ml min -1 m -2 and serum potassium increase of +0.30 mmol l -1 in HFrEF, enabling individualized expectations for therapy combinations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.